Drukke periode voor de boeg.
AASLD
November 12-15, 2021
ARO-AAT Treatment Reduces Intra-hepatic Z-AAT Leading to Improved Parameters of Liver Health and Fibrosis Regression
Session: Late-breaking Abstract Posters
ARO-HSD, An Investigational RNAi Therapeutic, Demonstrates Reduction in ALT and Hepatic HSD17B13 mRNA and Protein in Patients with NASH or Suspected NASH
Session: Late-breaking Abstract Posters
JNJ-3989 Efficacy and Safety of the siRNA JNJ-3989 and/or the Capsid Assembly Modulator (CAM) JNJ-6379 for the Treatment of Chronic Hepatitis B Virus Infection (CHB): Results from the Phase 2B REEF-1 Study
Session: Late Breaking Session 2
-----------------------
AHA Scientific Sessions 2021
November 13-17, 2021
ARO-APOC3, an Investigational RNAi Therapeutic, Shows Similar Efficacy and Safety in Genetically Confirmed FCS and Non-FCS Participants with Severe Hypertriglyceridemia
Session: The Future of Lipidology: Novel and Emerging Interventions for Lipid Disorders
----------------------
Jefferies London Healthcare Conference
November 16, 2021
at 3:50 p.m. GMT – Chris Anzalone, Ph.D., Arrowhead’s president and CEO, will participate in a fireside chat presentation
----------------------
Arrowhead Pharmaceuticals to Webcast Fiscal 2021 Year End Results
November 22, 2021,
at 4:30 p.m. ET to discuss its financial results for the fiscal year ended September 30, 2021.
---------------------
Piper Sandler 33rd Annual Healthcare Conference
November 30, 2021
Chris Anzalone, Ph.D., Arrowhead’s president and CEO, will participate in a fireside chat presentation